Cargando…
Targeting Oncogenic BRAF: Past, Present, and Future
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a “precision medicine” paradigm to diagnose and treat BRAF-driven tumors. Although targeted kinase inhibitors against BRAF are effective in a subset of mutant BRAF tumors, resistance to the therapy i...
Autores principales: | Zaman, Aubhishek, Wu, Wei, Bivona, Trever G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721448/ https://www.ncbi.nlm.nih.gov/pubmed/31426419 http://dx.doi.org/10.3390/cancers11081197 |
Ejemplares similares
-
Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021) -
Quantitative Framework for Bench-to-Bedside Cancer Research
por: Zaman, Aubhishek, et al.
Publicado: (2022) -
The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
por: Djanani, Angela, et al.
Publicado: (2020) -
EGFR targeted therapy resistance: current status, challenges, and future outlook
por: Bivona, Trever G.
Publicado: (2020) -
Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer
por: Wu, Wei, et al.
Publicado: (2017)